Other Emerging Cellular Therapies represent an exciting and rapidly evolving area in the treatment of hematologic cancers and blood disorders. These therapies involve the manipulation of a patient's own cells or donor cells to fight cancer, enhance immune responses, or restore blood cell production. In addition to CAR-T therapy, other cellular therapies that are gaining attention include natural killer (NK) cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and mesenchymal stem cell (MSC) therapy. Natural killer (NK) cell therapy involves the infusion of NK cells, which are part of the body's innate immune system and play a critical role in targeting and killing tumor cells without needing prior sensitization. These cells can be sourced from the patient or a donor and are genetically modified in some cases to enhance their cancer-killing capabilities. Tumor-infiltrating lymphocyte (TIL) therapy uses T-cells that are isolated from a patient’s tumor, expanded in the lab, and then reinfused to specifically target and destroy cancer cells. This approach is still in clinical trials but has shown promising results, particularly in solid tumors and some hematologic cancers. Mesenchymal stem cell (MSC) therapy has also shown potential in hematology, particularly in graft-versus-host disease (GVHD) after stem cell transplants. MSCs can modulate the immune system, reduce inflammation, and promote tissue repair, making them a potential tool for managing GVHD or enhancing the engraftment of donor cells.